TRCT
CCEL icon

Tower Research Capital (TRC)’s Cryo-Cell International CCEL Stock Holding History

Tower Research Capital (TRC)’s Portfolio CCEL Stock Details CCEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,222
Closed -$4.2K – 5154
2025
Q4 		$4.2K Sell
1,222
-20
-2% -$83 ﹤0.01% 4243
2025
Q3 		$5.76K Buy
1,242
+778
+168% +$3.69K ﹤0.01% 4203
2025
Q2 		$2.41K Sell
464
-1,323
-74% -$6.98K ﹤0.01% 4655
2025
Q1 		$11.4K Buy
1,787
+778
+77% +$5.65K ﹤0.01% 3542
2024
Q4 		$7.48K Buy
1,009
+390
+63% +$2.94K ﹤0.01% 4068
2024
Q3 		$3.94K Buy
+619
New +$4.27K ﹤0.01% 4730
2023
Q3 		– Sell
-85
Closed -$517 – 5970
2023
Q2 		$517 Sell
85
-3,572
-98% -$17.3K ﹤0.01% 5608
2023
Q1 		$11K Buy
3,657
+1,548
+73% +$5.97K ﹤0.01% 4188
2022
Q4 		$9K Buy
2,109
+822
+64% +$3.94K ﹤0.01% 4169
2022
Q3 		$8K Sell
1,287
-853
-40% -$5.26K ﹤0.01% 4763
2022
Q2 		$13K Sell
2,140
-626
-23% -$4K ﹤0.01% 4195
2022
Q1 		$21K Buy
2,766
+2,753
+21,177% +$25.4K ﹤0.01% 3475
2021
Q4 		$0 Buy
13
+6
+86% +$75 ﹤0.01% 6157
2021
Q3 		$0 Buy
+7
New +$86 ﹤0.01% 5793

Other funds holding CCEL

SA
SFI Advisors Montclair, New Jersey $95.2M AUM 23.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Tower Research Capital (TRC)'s CCEL Position: Q1 2026 in Review

Tower Research Capital (TRC) sold out of Cryo-Cell International (CCEL) in Q1 2026, closing a stake of 1,222 shares — an estimated $4.2K sold.

Tower Research Capital (TRC) first reported a position in CCEL in Q3 2021 and held it in 14 quarters. The position peaked at $21K in Q1 2022. 11 funds tracked by Wall St. Rank hold CCEL as of Q1 2026.

  • Tower Research Capital (TRC) reported no remaining Cryo-Cell International position as of Q1 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 1,222 Cryo-Cell International shares in Q1 2026, an estimated $4.2K.
  • Tower Research Capital (TRC) first reported a position in Cryo-Cell International in Q3 2021 and held it in 14 quarters.
  • Tower Research Capital (TRC)'s Cryo-Cell International position peaked at $21K in Q1 2022.
  • 11 funds tracked by Wall St. Rank held Cryo-Cell International as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.